J&J's Medical Devices & Diagnostics Announces Expansion with Innovative Products, Customer-Focused Solutions

At a meeting today with members of the investment community, senior leaders from the Medical Devices and Diagnostics (MD&D) segment of Johnson & Johnson

will outline plans to improve patient outcomes and expand their market leadership through innovative products, new business models and a significant focus on fast-growing emerging markets. Creating Value through Innovation Johnson & Johnson's MD&D segment is the world's largest medical devices and diagnostics business, with $28.5 billion in total sales for 2013, driven by ten $1 billion-plus platforms that hold the number one or number two positions in their respective categories. The company's MD&D businesses compete in approximately 30 percent of the estimated $370 billion global market, and many of the key markets in which these businesses compete are projected to grow faster than the overall market over the next 5 years. To expand its global leadership position, the MD&D segment invested nearly $1.8 billion in research and development in 2013. The company's MD&D businesses are positioned for continued growth with many recently launched products and a pipeline of more than 30 major product filings planned by the end of 2016. This meaningful innovation is intended to help health care systems, governments and providers improve clinical outcomes, increase patient satisfaction and contain costs; three tenets shared by most global health care reform acts, known widely as the Triple Aim. "Our businesses are uniquely positioned to continue helping patients while also leading the industry by capitalizing on our breadth, depth and scale," said Dominic J. Caruso, Vice President, Finance and Chief Financial Officer for Johnson & Johnson. "We are developing innovative products and working with health care systems on customer-focused solutions to ultimately improve outcomes for patients." Global Reach, Local Focus The medical device segment of emerging markets is growing three-to-four times faster than the developed markets, and with almost $6 billion in sales in the MD&D segment coming from these markets – more than 20 percent of its worldwide 2013 sales – Johnson & Johnson is leading the industry. Through innovative partnerships and dedicated strategies to meet the significant unmet needs of patients in emerging markets, Johnson & Johnson is well positioned to lead through the current evolution health care is experiencing worldwide. In Russia, the company's Vision Care business is piloting new business models to engage both eye care professionals and consumers. The acquisition of Spectrum Vision, which is to be fully integrated this year, dramatically increases the company's market penetration and customer service quality. Today, more than 85 percent of ACUVUE^® Brand Contact Lenses can be delivered the same or the next day across all time zones in Russia --  addressing the consumer's need for speed and convenience. The company's MD&D segment grew at 18 percent* operationally in China in 2013 with sales of approximately $1.4 billion, making it the largest of Johnson & Johnson's three business segments in the country. In 2013, the orthopaedic business received approval to manufacture and distribute trauma products from its plant in Suzhou. As the products launch this year, this local-supplier model will give the company access to a new market segment and new reimbursement opportunities. In China, the company's Diabetes Solutions business has a number one market position in a country that is home to a quarter of all of the world's diabetics. The business has signed an exclusive original equipment manufacturer (OEM) agreement with Nova Biomedical Corporation to market StatStrip^® point-of-care blood glucose testing systems to hospital customers in China - demonstrating its commitment to serving the needs of emerging markets. "We have a strong business in both developed and emerging markets," said Mr. Caruso. "Building on our 28 year history in China, we are capitalizing on our established footprint to grow and expand our overall business." Excellence in Execution DePuy Synthes Companies, the orthopaedics business of the MD&D segment, continues to lead in an attractive and evolving worldwide market. DePuy Synthes is realizing revenue and cost synergies from its integration and has established a strong foundation for capturing the full growth potential of the combined businesses. The business is also today announcing the launch of three new products: o The GLOBAL^® UNITE^® Anatomic Shoulder System is part of a larger platform enabling surgeons to repair or replace shoulders in a simpler and more efficient manner while optimizing the patient's range of motion. o The CORAIL^® Revision Hip System is the first tapered wedge revision system in the U.S. and is engineered to reduce the operating room footprint while delivering patient benefits through its bone-preserving design. o The TRUMATCH^® Resection Guide for the recently launched ATTUNE^® Rotating Platform Knee. TRUMATCH^® Personalized Solutions provides patient-specific instruments developed from a CT scan to reduce surgical steps and customize the procedure to each patient. The Global Surgery business of Johnson & Johnson is focusing on leveraging its scale to deliver a pipeline of innovative products that serve large, unmet health care needs, providing both clinical and economic benefits. The Global Surgery business has several key products whose innovation is expected to significantly drive growth for the company, including: o HARMONIC ACE^®+ 7 Shears with Advanced Hemostasis – the first purely ultrasonic device with a 7mm vessel sealing indication (Ethicon) o EVARREST™ Fibrin Sealant Patch to stop bleeding (Ethicon) o THERMOCOOL^® SMARTTOUCH™ Contact Force Sensing Catheter for atrial fibrillation (Biosense Webster) o INCRAFT^® Stent Graft System for abdominal aortic aneurysms (AAA) (Cordis) Leading with Purpose The Johnson & Johnson mission is to care for the world one person at a time. Last year, Johnson & Johnson donated more than $1 billion in products and services around the world, making life-changing, long-term differences in human health. The businesses in the MD&D segment are leading with purpose through their support of organizations that educate and help patients return to living healthy, active lives, and through global training centers and institutes that are enhancing the standard of care in emerging markets. About Today's Meeting The meeting will be live-streamed via webcast starting at 9:30 a.m. today and can be accessed along with the meeting agenda, list of speakers, speaker bios, and full copies of the presentations via the Johnson & Johnson Investor Relations website www.investor.jnj.com.  A replay and podcast will be available approximately two hours after the live webcast. A live Twitter feed for today's meeting is accessible via #JNJMDD14.